Allergic RhinitisPhase 3NCT03755557
Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray
A Phase 3 study testing Rhinocort and Budesolv in people with Allergic Rhinitis and Allergic Conjunctivitis, run by Marinomed Biotech AG at 1 site in Austria.
Trial summary
Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic rhinitis, especially in treatment of persistent symptoms. Budesonide, a non-halogenic glucocorticoid, is widely used in the management of inflammatory mucosal diseases like chronic obstructive pulmonary disease, asthma and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Allergic Rhinitis, Allergic Conjunctivitis, Hayfever
- What is being tested?
- Rhinocort and Budesolv
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 82 participants
- Where
- 1 siteAustria
- Study dates
- 19 Nov 2018to 5 Apr 2019
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- Written informed consent obtained before any trial related procedures are performed
- Healthy male or female subjects aged 18 years or older
- Female subjects of child-bearing potential must have a negative pregnancy test and be willing to practice appropriate contraceptive methods until the end of treatment visit
- A documented clinically relevant allergic history of moderate to severe SAR to grass pollen for the previous two years
- Subjects exhibit a moderate to severe response to approximately 1500 grass pollen grains/m3 within the first 2 hours in the Vienna Challenge Chamber, which is defined as total nasal symptom score (TNSS) of at least 6 (out of 12) using standard VCC grass pollen allergen mixture. Nasal symptom score is the sum of "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing", each of which have been scored on a categorical scale from 0 to 3.
Show all 15Show fewer
- Positive Skin Prick Test (SPT) response (wheal diameter at least 3 mm larger than diluent control) to grass pollen SPT solutions (standard Allergopharma) at screening or within the last 6 months prior to study start.
- Positive serum specific IgE against recombinant major allergen components of the used grass pollen (specific CAP IgE ≥0.70 kU/L) at screening or within the last 6 months prior to study start.
- Patients with a body weight of ≥ 50kg and a body mass index within the range of 19-30kg/m2.
- Non-smoking subjects (smoked <10 packs years in their lifetime and had not smoked in the last 6 months)
- Asthma patients only if the asthma condition is mild or intermittent, and if those are not treated with steroids
- Subject has a forced expiratory volume in 1 second (FEV1) of at least 80% of predicted value (ECCS) at the screening.
- Subject is capable of understanding the study procedures and potential risks associated with the study, and voluntarily agrees to participate by giving written informed consent.
- Subject is able to adhere to dose and visit schedules.
- Subject is able to read, understand and complete questionnaires and diaries.
Who cannot join
- A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Pregnant, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method (pregnancy to be controlled by a pregnancy dipstick test).
- A clinical history of uncontrolled asthma within 3 months prior to screening.
- Subjects with asthma requiring treatment with inhaled corticosteroids on a regular basis judged by the investigator.
- Previous successful immunotherapy to grass pollen, a grass pollen allergen or a cross-reacting allergen within the past 3 years.
- Ongoing treatment with any allergen-specific immunotherapy product.
Show all 27Show fewer
- Subjects with a current oral candidiasis infection or treatment for oral candidiasis during the last 30 days before starting the study.
- Subjects with history of tuberculosis.
- Subjects with any fungal/viral/bacterial respiratory or systemic infections during the last 30 days.
- Symptoms of or treatment for upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infectious process at randomization.
- Clinically relevant nasal polyps, medical history of paranasal sinus surgery and/or medical history of surgery of nasal turbinates judged by the investigator.
- Subjects with glaucoma or a family history of glaucoma.
- Subjects using any ophthalmic steroids during the last 30 days.
- Subjects treated with nasal, inhaled or systemic steroids during the last 30 days.
- History of anaphylaxis with cardiorespiratory symptoms (immunotherapy, exercise induced, food allergy, drugs or an idiopathic reaction).
- Any clinically relevant chronic disease judged by the investigator.
- Systemic disease affecting the immune system judged by the investigator.
- Use of an investigational drug within 30 days/5 half-lives of the drug (which ever longest) prior to screening.
- History of allergy, hypersensitivity or intolerance to any ingredients of the IMP.
- History of alcohol or drug abuse.
- Being immediate family of the investigator or trial staff, defined as the investigator's/staff's spouse, parent, child, grandparent or grandchild.
- Subjects with previous SAR that has proven unresponsive to steroid therapy.
- Subjects treated with leukotriene antagonists (1 month before study start), long-lasting anti-histamines, like cetirizine, fexofenandine, loratadine, desloratadine, hydroxyzine (5 to 10 days before study start), mast cell stablizier (2 weeks before study start) or nasal decongestant (3 days before study start).
- Subjects with an acute or chronic sinusitis judged by the investigator.
- Subjects with hypersensitivity to corticosteroids judged by the investigator.
- Subjects with ocular herpes simplex infections.
- Subjects with cataracts and with cataract history.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Demonstration of Therapeutic Equivalence/Non-inferiority as Well as Early Onset of Action of the Novel Water-soluble Budesonide Nasal Spray (Budesolv 10) Compared With Marketed Rhinocort® Aqua 64 in Patients Suffering From Grass Pollen Induced Allergic Rhinitis
Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic rhinitis, especially in treatment of persistent symptoms.
Budesonide, a non-halogenic glucocorticoid, is widely used in the management of inflammatory mucosal diseases like chronic obstructive pulmonary disease, asthma and allergic rhinitis. It is a highly fat-soluble substance with low water solubility and is presented as dispersion in marketed nasal sprays, like Rhinocort aqua 64. The maximum therapeutic efficacy of Rhinocort aqua is obtained after an application period of 7 to 14 days. In Budesolv, the solubility of budesonide is considerably increased suggesting that the same therapeutic efficacy can be reached with a lower dose. Better bioavailability of the dissolved drug promise an earlier onset of therapeutic efficacy. The current trial is undertaken to demonstrate these two effects. Subjects suffering from grass pollen allergic rhinitis will be challenged with grass pollen in a challenge chamber.
Read more
Allergic subjects will be treated with two actuations (50 μl) of respective study treatment into each nostril once daily for 8 days. The total daily budesonide dose will be 40 μg per subject for Budesolv 10 and 256 μg per subject for Rhinocort® aqua 64. The primary objective of the study is to show non-inferiority of Budesolv 10 to Rhinocort® aqua 64. On day 8 grass pollen allergic patients will be challenged with grass pollen over a period of 6 hours and subjective nasal symptoms (congestion, sneezing, itching, rhinorrhea) as well as objective symptoms (nasal airflow, nasal secretion) will be assessed every 15 minutes.
The second objective of the trial is to demonstrate an early on-set of therapeutic efficacy of Budesolv 10 compared to Rhinocort aqua. On day 1, grass pollen allergic patients will be challenged with grass pollen allergen in the challenge chamber over a period of 6 hours. After 1 hour 45 minutes, patients will receive their first dosage of the respective nasal spray treatment. During the 6 hour grass pollen challenge, subjective and objective endpoints will be measured every 15 minutes.
To eliminate an individual bias based on expectations, the effect and onset of action is also compared to the effects of a suitable placebo. The same set of study participants will receive all three interventions in three consecutive treatment periods.
Read the detailed description
This is a randomized, placebo controlled, three way cross over, double-blind, single site trial in adult subjects (18 years of age and older) who demonstrate grass specific Immunglobulin E (IgE) reactivity and have a history of grass pollen induced allergic rhinitis/rhinoconjunctivitis with or without controlled asthma. In the cross-over setting three treatments, namely placebo, Budesolv 10 or Rhinocort® aqua 64 will be evaluated.
The primary objective of the trial is to demonstrate therapeutic equivalence/non-inferiority between Budesolv 10 and Rhinocort® aqua 64, a marketed comparator containing the same compound (budesonide), in patients suffering from grass pollen induced allergic rhinitis/rhinoconjunctivitis with or without controlled asthma on day 8 of treatment. A placebo group will be introduced to show effectiveness of treatment and hence validate the trial design.
The evaluation will be based on the assessment of rhinitis symptoms during grass pollen challenge performed in the Vienna Challenge Chamber (environmental exposure chamber).
Secondary objective of the trial is the early onset of action of Budesolv 10 compared to Rhinocort® aqua 64, determined on day one of treatment.
Visit 1 + 2 - Screening + Inclusion period:
Subjects will be screened for appropriate allergic response. A total nasal symptom score (TNSS) of at least 6 points out of 12 within the first two hours in the grass pollen challenge chamber is required to be included into the study.
Visit 3 + 5 + 7 / "day 1":
Eligible subjects will be randomly assigned to one of the three treatment arms (fully blinded) in the order of their screening numbers assigned at visit 1. Subjects will enter the study site about one hour ahead of the start of allergen provocation. After positive completion of all study relevant assessments, subjects enter the grass pollen challenge chamber for subjective and objective assessments for a period of 6 hours. One hour forty-five minutes after entry, the first treatment will be applied.
The subjective nasal symptom score will be recorded every fifteen minutes during a 6-hour allergen exposure challenge. Every hour rhinomanometry will be performed to objectively evaluate the respiratory function of the nose. Additional rhinomanometry will be performed at two hours 30 minutes after entry. Subjects will continue treatment with two actuations into each nostril once a day until day 7.
Visit 4 + 6 + 8 / "day 8":
On day 8 of their respective treatment block, subjects will enter the study site about two hours before provocation will start. Subjects will take their last treatment dosage approximately one hour before entering the challenge chamber. The study medication device will be returned to study site staff for external analytical evaluations after usage (in-use-stability test). After receiving their last treatment dose and shortly before entering the challenge chamber, baseline symptom score will be assessed. Like on day one, subjects will be provoked for 6 hours with grass pollen allergens. Subjective symptom scores will be recorded every fifteen minutes, and rhinomanometry will be performed every hour during the challenge.
Between the respective study treatments, a wash-out period of at least 20 days must be adhered to allowing complete dissipation of the previous treatment. After the wash-out period, subjects change to the next treatment block in the sequence. During the entire trial, subjects will be asked to monitor for adverse events (AEs), and they will record the use of concomitant medications on the provided form. Female subjects of child-bearing potential will complete a urine pregnancy test in the course of all visits.
Following parameters will be assessed:
- Subjective symptom score (nasal, ocular, respiratory) during a grass pollen challenge lasting for 6 hours - every 15 minutes Active anterior rhinomanometry (AAR) - every 60 minutes, additional measurement on day 1 at 2:30 after entry.
- Lung function tests using regular spirometry for FEV1 and FVC - every 120 minutes
- Nasal secretion weight - every 30 minutes
- Physical examination - at Screening and Follow up
- Vital signs - every visit, pre- and post-challenge
- Safety laboratory assessments: Complete blood count with differential, blood chemistry, liver function, urine dipstick test - at screening and last treatment visit, serology at screening and drug abuse test on investigator's decision
- Skin Prick Test with skin prick test solution (Manufacturer Allergopharma) - at Screening or within the previous 6 months
- Specific CAP analysis (g6) - at Screening or within the previous 6 months
- ECG - at screening and Follow up
- Adverse events - throughout the study
- Concomitant medication - throughout the study One week after the final provocation session, subjects will complete the trial after their follow up visit. Validated methods of data collection, analysis, and evaluation will be used for the trial.
The trial endpoints are listed below:
Primary efficacy endpoint:
The primary efficacy endpoint will be the mean 'Total Nasal Symptom Score' (TNSS), calculated as the baseline adjusted mean of TNSS measured at 17 time points (every 15 minutes) during the grass pollen allergen exposure challenge from time point 2 to 6 hours on day 8.
The TNSS is the sum of the symptoms "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing". Each individual symptom will be scored on a 4-point categorical scale from 0-3 (where "0"= none "1"=mild "2"=moderate "3"=severe).
Key Secondary efficacy endpoint:
Time point when onset of action can be observed.
Additional secondary efficacy endpoints:
- Nasal airflow: will be assessed every hour during the six hour grass pollen allergen exposure challenge
- Nasal secretion: will be assessed every 30 minutes during the six-hour grass pollen allergen exposure challenge. Additional rhinomanometry will be done on day 1 at 2:30 h after entry in the challenge chamber
- Total ocular symptom score (TOSS) is the sum of the symptoms "ocular itching", "redness", "watery eyes".
- Total asthma symptom score (TASS) is the sum of the symptoms "cough", "wheeze", "dyspnea".
Each individual symptom of TOSS and TASS will be scored on a 4-point categorical scale from 0-3 (where "0"= none "1"=mild "2"=moderate "3"=severe). TOSS and TASS will be assessed every 15 minutes during the six-hour grass pollen allergen exposure challenge.
Safety endpoints:
- Adverse events (AEs)
- Safety laboratory
- ECG
- Spirometry (FeV1, FVC)
- Conditions
- Allergic Rhinitis, Allergic Conjunctivitis, Hayfever
- Being tested
- Rhinocort, Budesolv, Placebo
- Keywords
- budesonide, allergic rhinitis, allergic rhinoconjuntivitis, allergen exposure chamber, onset of action, therapeutic equivalence, total nasal symptom score, hayfever, glucocorticosteroids, nasal congestion, Vienna Challenge Chamber, Carragelose, Carrageenan, Iota-Carrageenan
- Medical subject headings
- Rhinitis, Allergic, Conjunctivitis, Allergic, Rhinitis, Allergic, Seasonal, Nasal Obstruction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RhinocortDrug
Also called Budesonide
Application of a nasal spray
BudesolvDrug
Also called Budesonide
Application of a nasal spray
PlaceboOther
Also called buffered saline
Application of a nasal spray
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Application of a placebo nasal spray once daily for 8 days Nasal Sprays Receives: Other: Placebo |
| Rhinocort | Active comparator | Nasal Sprays Application of "Rhinocort Aqua 64 micrograms, nasal spray" once daily for 8 days. Daily dosage 256 µg/d Receives: Drug: Rhinocort |
| Budesolv | Experimental | Application of a Budesolv 10 micrograms, nasal spray once daily for 8 days. Daily dosage 40 µg/d Nasal Sprays Receives: Drug: Budesolv |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total Nasal Symptom Score
subjective compound score evaluating "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total nasal symptom score (0 - 12)
Measured: 2 - 6 hours of allergen challenge
Secondary outcomes (4)
Total Ocular Symptom Score
subjective compound score evaluating "ocular itching", "redness", "watery eyes" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total ocular symptom score (0 - 9)
Measured: 2 - 6 hours of allergen challenge
Total Asthma Symptom Score
subjective compound score evaluating "cough", "wheeze", "dyspnea" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total asthma symptom score (0 - 9)
Measured: 2 - 6 hours of allergen challenge
Nasal airflow
Rhinomanometry
Measured: 0 - 6 hours of allergen challenge
Nasal secretion
tissue weight
Measured: 0 - 6 hours of allergen challenge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2018
- Study start19 Nov 2018
- Primary completion5 Apr 2019
- Study completion5 Apr 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Allergic RhinitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- 3-way crossover, randomized, prospective, placebo-controlled, double blinded study in a validated allergen exposure chamber setting using grass pollen allergen
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 82 participants (actual)
Sponsor and investigators
- Lead sponsor
- Marinomed Biotech AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Eva E Prieschl-Grassauer, PhD, Study chair, Marinomed Biotech AG
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03755557
- Sponsor's protocol ID
- BDS_18_01
- Other IDs
- 2018-001324-19, 2018
- Status last verified
- Oct 2020
- First submitted
- 21 Nov 2018
- Last updated
- 12 Oct 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Murdoch RD, Bareille P, Ignar D, Miller SR, Gupta A, Boardley R, Zieglmayer P, Zieglmayer R, Lemel P, Horak F. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy. 2015 Aug;45(8):1346-55. doi: 10.1111/cea.12556.
PubMed 25900517
Study at a glance
From the registry record, last updated by the sponsor on 12 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Demonstration of Therapeutic Equivalence/Non-inferiority as Well as Early Onset of Action of the Novel Water-soluble Budesonide Nasal Spray (Budesolv 10) Compared With Marketed Rhinocort® Aqua 64 in Patients Suffering From Grass Pollen Induced Allergic Rhinitis
- ClinicalTrials.gov ID
- NCT03755557
- Acronym / sponsor ID
- BDS_18_01
- Conditions
- Allergic Rhinitis, Allergic Conjunctivitis, Hayfever
- Keywords
- budesonide, allergic rhinitis, allergic rhinoconjuntivitis, allergen exposure chamber, onset of action, therapeutic equivalence, total nasal symptom score, hayfever
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 82 participants (actual)
- Lead sponsor
- Marinomed Biotech AGIndustry (pharma, biotech, devices)
- Study start
- 19 Nov 2018 (actual)
- Primary completion
- 5 Apr 2019 (actual)
- Study completion
- 5 Apr 2019 (actual)
- First posted
- 28 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intranasal corticosteroids are accepted as safe and effective first-line therapy for allergic rhinitis, especially in treatment of persistent symptoms.
Budesonide, a non-halogenic glucocorticoid, is widely used in the management of inflammatory mucosal diseases like chronic obstructive pulmonary disease, asthma and allergic rhinitis. It is a highly fat-soluble substance with low water solubility and is presented as dispersion in marketed nasal sprays, like Rhinocort aqua 64. The maximum therapeutic efficacy of Rhinocort aqua is obtained after an application period of 7 to 14 days. In Budesolv, the solubility of budesonide is considerably increased suggesting that the same therapeutic efficacy can be reached with a lower dose. Better bioavailability of the dissolved drug promise an earlier onset of therapeutic efficacy. The current trial is undertaken to demonstrate these two effects. Subjects suffering from grass pollen allergic rhinitis will be challenged with grass pollen in a challenge chamber.
Allergic subjects will be treated with two actuations (50 μl) of respective study treatment into each nostril once daily for 8 days. The total daily budesonide dose will be 40 μg per subject for Budesolv 10 and 256 μg per subject for Rhinocort® aqua 64. The primary objective of the study is to show non-inferiority of Budesolv 10 to Rhinocort® aqua 64. On day 8 grass pollen allergic patients will be challenged with grass pollen over a period of 6 hours and subjective nasal symptoms (congestion, sneezing, itching, rhinorrhea) as well as objective symptoms (nasal airflow, nasal secretion) will be assessed every 15 minutes.
The second objective of the trial is to demonstrate an early on-set of therapeutic efficacy of Budesolv 10 compared to Rhinocort aqua. On day 1, grass pollen allergic patients will be challenged with grass pollen allergen in the challenge chamber over a period of 6 hours. After 1 hour 45 minutes, patients will receive their first dosage of the respective nasal spray treatment. During the 6 hour grass pollen challenge, subjective and objective endpoints will be measured every 15 minutes.
To eliminate an individual bias based on expectations, the effect and onset of action is also compared to the effects of a suitable placebo. The same set of study participants will receive all three interventions in three consecutive treatment periods.
Detailed description
This is a randomized, placebo controlled, three way cross over, double-blind, single site trial in adult subjects (18 years of age and older) who demonstrate grass specific Immunglobulin E (IgE) reactivity and have a history of grass pollen induced allergic rhinitis/rhinoconjunctivitis with or without controlled asthma. In the cross-over setting three treatments, namely placebo, Budesolv 10 or Rhinocort® aqua 64 will be evaluated.
The primary objective of the trial is to demonstrate therapeutic equivalence/non-inferiority between Budesolv 10 and Rhinocort® aqua 64, a marketed comparator containing the same compound (budesonide), in patients suffering from grass pollen induced allergic rhinitis/rhinoconjunctivitis with or without controlled asthma on day 8 of treatment. A placebo group will be introduced to show effectiveness of treatment and hence validate the trial design.
The evaluation will be based on the assessment of rhinitis symptoms during grass pollen challenge performed in the Vienna Challenge Chamber (environmental exposure chamber).
Secondary objective of the trial is the early onset of action of Budesolv 10 compared to Rhinocort® aqua 64, determined on day one of treatment.
Visit 1 + 2 - Screening + Inclusion period:
Subjects will be screened for appropriate allergic response. A total nasal symptom score (TNSS) of at least 6 points out of 12 within the first two hours in the grass pollen challenge chamber is required to be included into the study.
Visit 3 + 5 + 7 / "day 1":
Eligible subjects will be randomly assigned to one of the three treatment arms (fully blinded) in the order of their screening numbers assigned at visit 1. Subjects will enter the study site about one hour ahead of the start of allergen provocation. After positive completion of all study relevant assessments, subjects enter the grass pollen challenge chamber for subjective and objective assessments for a period of 6 hours. One hour forty-five minutes after entry, the first treatment will be applied.
The subjective nasal symptom score will be recorded every fifteen minutes during a 6-hour allergen exposure challenge. Every hour rhinomanometry will be performed to objectively evaluate the respiratory function of the nose. Additional rhinomanometry will be performed at two hours 30 minutes after entry. Subjects will continue treatment with two actuations into each nostril once a day until day 7.
Visit 4 + 6 + 8 / "day 8":
On day 8 of their respective treatment block, subjects will enter the study site about two hours before provocation will start. Subjects will take their last treatment dosage approximately one hour before entering the challenge chamber. The study medication device will be returned to study site staff for external analytical evaluations after usage (in-use-stability test). After receiving their last treatment dose and shortly before entering the challenge chamber, baseline symptom score will be assessed. Like on day one, subjects will be provoked for 6 hours with grass pollen allergens. Subjective symptom scores will be recorded every fifteen minutes, and rhinomanometry will be performed every hour during the challenge.
Between the respective study treatments, a wash-out period of at least 20 days must be adhered to allowing complete dissipation of the previous treatment. After the wash-out period, subjects change to the next treatment block in the sequence. During the entire trial, subjects will be asked to monitor for adverse events (AEs), and they will record the use of concomitant medications on the provided form. Female subjects of child-bearing potential will complete a urine pregnancy test in the course of all visits.
Following parameters will be assessed:
- Subjective symptom score (nasal, ocular, respiratory) during a grass pollen challenge lasting for 6 hours - every 15 minutes Active anterior rhinomanometry (AAR) - every 60 minutes, additional measurement on day 1 at 2:30 after entry.
- Lung function tests using regular spirometry for FEV1 and FVC - every 120 minutes
- Nasal secretion weight - every 30 minutes
- Physical examination - at Screening and Follow up
- Vital signs - every visit, pre- and post-challenge
- Safety laboratory assessments: Complete blood count with differential, blood chemistry, liver function, urine dipstick test - at screening and last treatment visit, serology at screening and drug abuse test on investigator's decision
- Skin Prick Test with skin prick test solution (Manufacturer Allergopharma) - at Screening or within the previous 6 months
- Specific CAP analysis (g6) - at Screening or within the previous 6 months
- ECG - at screening and Follow up
- Adverse events - throughout the study
- Concomitant medication - throughout the study One week after the final provocation session, subjects will complete the trial after their follow up visit. Validated methods of data collection, analysis, and evaluation will be used for the trial.
The trial endpoints are listed below:
Primary efficacy endpoint:
The primary efficacy endpoint will be the mean 'Total Nasal Symptom Score' (TNSS), calculated as the baseline adjusted mean of TNSS measured at 17 time points (every 15 minutes) during the grass pollen allergen exposure challenge from time point 2 to 6 hours on day 8.
The TNSS is the sum of the symptoms "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing". Each individual symptom will be scored on a 4-point categorical scale from 0-3 (where "0"= none "1"=mild "2"=moderate "3"=severe).
Key Secondary efficacy endpoint:
Time point when onset of action can be observed.
Additional secondary efficacy endpoints:
- Nasal airflow: will be assessed every hour during the six hour grass pollen allergen exposure challenge
- Nasal secretion: will be assessed every 30 minutes during the six-hour grass pollen allergen exposure challenge. Additional rhinomanometry will be done on day 1 at 2:30 h after entry in the challenge chamber
- Total ocular symptom score (TOSS) is the sum of the symptoms "ocular itching", "redness", "watery eyes".
- Total asthma symptom score (TASS) is the sum of the symptoms "cough", "wheeze", "dyspnea".
Each individual symptom of TOSS and TASS will be scored on a 4-point categorical scale from 0-3 (where "0"= none "1"=mild "2"=moderate "3"=severe). TOSS and TASS will be assessed every 15 minutes during the six-hour grass pollen allergen exposure challenge.
Safety endpoints:
- Adverse events (AEs)
- Safety laboratory
- ECG
- Spirometry (FeV1, FVC)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- 3-way crossover, randomized, prospective, placebo-controlled, double blinded study in a validated allergen exposure chamber setting using grass pollen allergen
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Other: PlaceboApplication of a placebo nasal spray once daily for 8 days Nasal Sprays |
| Rhinocort | Active comparator | Drug: RhinocortNasal Sprays Application of "Rhinocort Aqua 64 micrograms, nasal spray" once daily for 8 days. Daily dosage 256 µg/d |
| Budesolv | Experimental | Drug: BudesolvApplication of a Budesolv 10 micrograms, nasal spray once daily for 8 days. Daily dosage 40 µg/d Nasal Sprays |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- Written informed consent obtained before any trial related procedures are performed
- Healthy male or female subjects aged 18 years or older
- Female subjects of child-bearing potential must have a negative pregnancy test and be willing to practice appropriate contraceptive methods until the end of treatment visit
- A documented clinically relevant allergic history of moderate to severe SAR to grass pollen for the previous two years
Key exclusion criteria (27 listed)
- A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Pregnant, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method (pregnancy to be controlled by a pregnancy dipstick test).
- A clinical history of uncontrolled asthma within 3 months prior to screening.
- Subjects with asthma requiring treatment with inhaled corticosteroids on a regular basis judged by the investigator.
- Previous successful immunotherapy to grass pollen, a grass pollen allergen or a cross-reacting allergen within the past 3 years.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RhinocortAlso: BudesonideApplication of a nasal spray | Drug | Rhinocort |
| BudesolvAlso: BudesonideApplication of a nasal spray | Drug | Budesolv |
| PlaceboAlso: buffered salineApplication of a nasal spray | Other | Placebo |
Primary outcome
Total Nasal Symptom Score
Time frame: 2 - 6 hours of allergen challenge
subjective compound score evaluating "nasal congestion", "rhinorrhea", "itchy nose" and "sneezing" from "0" (absent) to "3" (severe). The sum of sub-scores is reported as total nasal symptom score (0 - 12)
4 secondary outcomes
Total Ocular Symptom Score
Time frame: 2 - 6 hours of allergen challenge
Total Asthma Symptom Score
Time frame: 2 - 6 hours of allergen challenge
Nasal airflow
Time frame: 0 - 6 hours of allergen challenge
Nasal secretion
Time frame: 0 - 6 hours of allergen challenge
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Oct 2020.
- Background: PubMed 25900517Murdoch RD, Bareille P, Ignar D, Miller SR, Gupta A, Boardley R, Zieglmayer P, Zieglmayer R, Lemel P, Horak F. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy. 2015 Aug;45(8):1346-55. doi: 10.1111/cea.12556.
- Individual participant dataSharing planned: No
Related trials for Allergic Rhinitis
Not yet recruitingPhase 1
Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic Rhinitis
Chronic Allergic Rhinitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
Not yet recruitingObservational study
Prevelance of Bronchial Asthma and Allergic Rhinitis Among Children With Nephrotic Syndrom at Sohag University Hospital
Allergic Diseases in Nephrotic Children, Nephrotic Syndrom
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eva E Prieschl-Grassauer, PhD study chair
Marinomed Biotech AG
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Rhinocort and Budesolv in people with Allergic Rhinitis and Allergic Conjunctivitis, run by Marinomed Biotech AG at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total Nasal Symptom Score (time frame: 2 - 6 hours of allergen challenge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03755557, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2020.